Helen Torley
Chief Executive Officer presso HALOZYME THERAPEUTICS, INC.
Patrimonio netto: 28 M $ in data 31/03/2024
Profilo
Helen I. Torley occupa la posizione di presidente, amministratore delegato e direttore di Halozyme Therapeutics, Inc. Fa anche parte del consiglio di Quest Diagnostics, Inc. e di Director & Member-Health Section Governing Board presso Biotechnology Innovation Organization e membro del Royal College of Physicians. In passato è stata vicepresidente e GM-United States Bone Health presso Amgen, Inc. e Chief Commercial Officer & Executive VP per Onyx Pharmaceuticals, Inc. (una consociata di Amgen, Inc.), Vice Presidente-Affari medici di Novartis, Inc., Vice Presidente-Affari medici di Sandoz SA e Vice Presidente-Cardiovascular & Metabolic Sales di Bristol-Myers Squibb World Wide Medicines Group. Si è laureata all'Università di Glasgow.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
26/02/2024 | 676 744 ( 0.53% ) | 28 M $ | 31/03/2024 |
Posizioni attive di Helen Torley
Società | Posizione | Inizio |
---|---|---|
HALOZYME THERAPEUTICS, INC. | Chief Executive Officer | 06/01/2014 |
ANTARES PHARMA, INC. | Director/Board Member | 24/05/2022 |
The Royal College of Physicians | Corporate Officer/Principal | - |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Precedenti posizioni note di Helen Torley
Società | Posizione | Fine |
---|---|---|
QUEST DIAGNOSTICS INCORPORATED | Director/Board Member | 18/05/2022 |
RELYPSA INC | Director/Board Member | 01/09/2016 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Operating Officer | 15/12/2011 |
AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2002 |
Formazione di Helen Torley
University of Glasgow | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
AMGEN INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
QUEST DIAGNOSTICS INCORPORATED | Health Services |
HALOZYME THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Antares Pharma, Inc.
Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Sandoz SA |
- Borsa valori
- Insiders
- Helen Torley